查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2004926

強迫症治療市場：2026-2032年全球市場預測（依藥物類別、通路、藥物類型、給藥途徑、最終用戶及患者年齡層分類）

Obsessive-Compulsive Disorder Drugs Market by Drug Class, Distribution Channel, Drug Type, Route Of Administration, End User, Patient Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年強迫症 (OCD) 治療市場價值 10.5 億美元，預計到 2026 年將成長至 11.3 億美元，複合年成長率為 8.91%，到 2032 年將達到 19.1 億美元。

主要市場統計數據
基準年 2025 10.5億美元
預計年份：2026年 11.3億美元
預測年份 2032 19.1億美元
複合年成長率 (%) 8.91%

針對強迫症藥物治療的簡明臨床和商業性指南，將治療的細微差別與策略市場需求相結合。

目前，強迫症（OCD）的藥物治療現況亟需為臨床照護、產品開發和市場進入等領域的相關人員提供清晰簡潔的指南。本執行摘要首先重點介紹治療背景，強調強迫症臨床表現的複雜性、患者症狀的多樣性以及藥物治療與認知行為療法相結合的關鍵作用。透過強調實證治療路徑和現有藥物類別的多樣性，本概要為深入分析市場動態、監管影響和供應鏈考量奠定了基礎。

對科學、監管和商業性因素的融合將重塑強迫症藥物療法的開發路徑和市場進入策略進行詳細說明。

強迫症（OCD）的治療體係正經歷著一場變革，其驅動力來自不斷湧現的臨床證據、監管政策的調整以及藥物研發和遞送技術的進步。精準精神病學的最新進展以及對OCD亞型更精細的表現型分析，不僅明確了靶點識別，也重新激發了人們對現有抗憂鬱症和新型作用機制的興趣。同時，監管機構正在針對存在高度未滿足需求的適應症，明確適應性試驗設計和加速核准流程，從而改變研發進度和投資決策。

對 2025 年美國關稅措施將如何重塑強迫症藥物整個價值鏈的供應鏈、採購決策和價格談判進行全面分析。

美國於2025年實施的關稅措施的累積影響正逐漸顯現，並波及強迫症（OCD）藥物價值鏈的多個環節，迫使相關人員重新評估供應韌性、成本結構和籌資策略。關稅帶來的投入成本壓力尤其影響活性藥物成分和某些特殊輔料，迫使製造商評估替代供應商和生產地點，以在確保產品品質的同時維持獲利能力。這些調整與更廣泛的行業趨勢同步進行，例如雙重採購和加強庫存緩衝以降低未來貿易政策波動的風險。

根據藥物類別、通路、劑型和患者人口統計特徵進行策略性細分，以滿足差異化的商業性和臨床需求。

從精細的市場區隔觀點來看，強迫症（OCD）藥物治療領域存在著影響需求、盛行率和競爭壓力的差異化商業性動態。從藥物類別來看，主要的抗憂鬱症類別，例如單胺氧化酵素抑制劑（MAOIs）、5-羥血清素-正腎上腺素再回收抑制劑（SNRIs）、選擇性血清素再回收抑制劑（SSRIs）和三環抗憂鬱藥物，各自展現出不同的療效和耐受性特徵。其中，MAOIs的代表藥物包括苯乙肼和反苯環丙胺；SNRIs的代表藥物包括Desvenlafaxine、Duloxetine和文拉法辛；SSRIs的代表藥物包括西酞普蘭、Fluoxetine、氟伏沙明、帕羅西汀和舍曲林；TCAs的代表藥物包括阿米咪林、氯米米姆林丙嗪。這些細微的治療差異會影響處方模式、藥物變更傾向和長期用藥依從性。

提供切實可行的區域洞察，解釋美洲、歐洲、中東和非洲以及亞太地區的市場動態如何需要個人化的商業化和進入策略。

區域特徵對強迫症（OCD）藥物治療的研發、報銷和實施有顯著影響，因此需要製定針對特定區域的策略。在美洲，准入框架、支付方的多樣性以及蓬勃發展的民營市場，共同決定了市場准入策略和循證醫學證據生成（以支持處方集納入和報銷）的優先順序。該地區強調以結果為導向的合約和真實世界數據，以在不同的醫療服務模式下展現藥物價值。

對企業趨勢和競爭定位進行深入分析，重點在於塑造強迫症治療組合的創新、生命週期管理和夥伴關係策略。

強迫症 (OCD) 治療領域的競爭格局和企業發展趨勢反映出，創新投資、生命週期管理和夥伴關係關係正在融合，以解決產品可及性和差異化問題。各公司正增加對後期臨床計畫的投入，旨在提高療效和耐受性，使其優於現有標準療法；同時，他們也在透過改進配方、開發緩釋製劑和聯合治療等方式最佳化產品組合。隨著各公司尋求非藥物輔助療法以改善整體療效，與學術機構和數位醫療供應商的合作研究也日益普遍。

為高階主管提供實際有效的建議，以加強強迫症治療領域的供應韌性、證據產生和價值主導的商業化。

致力於鞏固自身在強迫症治療領域地位的產業領導者應優先採取一系列切實可行且影響深遠的措施，以增強自身韌性並實現商業性差異化。首先，他們應從試驗設計的早期階段就將衛生經濟學和結果研究納入考量，使臨床開發選擇與支付方的證據要求保持一致，並縮短獲得保險覆蓋的路徑。同時，他們應透過區域多元化和策略性生產合約來強化供應鏈，以降低貿易政策波動帶來的風險，並確保供應的連續性。

採用透明、多方面的研究途徑，結合關鍵相關人員的訪談和系統性的二手證據，提供可靠、可重複和具有策略意義的見解。

本次高階主管分析的基礎研究結合了第一手資料和第二手資料，以確保獲得全面而深入的見解。第一手資料包括對臨床醫生、付款者、採購負責人和生產專家進行結構化檢驗，以了解醫療機構的實際情況、處方行為和取得途徑的限制。第二手資料包括對同行評審的臨床文獻、監管指導文件、臨床試驗註冊資訊和公開的安全報告進行系統性回顧，以檢驗治療趨勢和證據缺口。

執行總結強調，整合臨床差異化、供應彈性和以患者為中心的策略對於在強迫症治療中取得永續的成果至關重要。

總之，現代強迫症（OCD）治療領域面臨臨床、監管和商業方面的雙重挑戰與機會。臨床認知的進步和輔助性數位化干涉措施的出現，正為改善患者預後鋪平道路；與此同時，貿易政策的轉變和學名藥競爭的加劇，正在重塑成本和供應動態。因此，決策者必須整合實證實踐、供應鏈韌性和以病人為中心的支援服務，制定符合當地市場實際情況和支付方期望的連貫策略。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：強迫症治療市場：依藥物類別分類

  • MAOI
    • 芬納嗪
    • 反式環丙胺
  • SNRI
    • Desvenlafaxine
    • Duloxetine
    • 文拉法辛
  • SSRI
    • 西洛普魯姆
    • Fluoxetine
    • 氟伏沙明
    • 帕羅西汀
    • 舍曲林
  • TCA
    • 阿米替林
    • 氯米帕明
    • 丙咪嗪

第9章 強迫症治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章：強迫症治療藥物市場－依藥物類型分類

  • 品牌藥
  • 非專利的

第11章 強迫症治療市場：依給藥途徑分類

  • 口服
  • 腸外

第12章 強迫症治療市場：依最終使用者分類

  • 診所
  • 醫院
  • 普通家庭

第13章：依患者年齡層分類的強迫症治療藥物市場

  • 成人版
  • 兒童

第14章 強迫症治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 強迫症治療市場：依群體分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 強迫症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國強迫症治療市場

第18章：中國強迫症治療藥物市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc
  • Alembic Pharmaceuticals Ltd
  • Amneal Pharmaceuticals Inc
  • Apotex Inc
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Biogen Inc
  • Dr Reddy's Laboratories Ltd
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • H Lundbeck A/S
  • Johnson & Johnson
  • Lupin Pharmaceuticals Inc
  • Mallinckrodt plc
  • Merck & Co Inc
  • Novartis AG
  • Omeros Corporation
  • Otsuka Pharmaceutical Co Ltd
  • Pfizer Inc
  • Sanofi
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd
  • Viatris Inc
  • Zydus Pharmaceuticals Inc
Product Code: MRR-742BD51822E2

The Obsessive-Compulsive Disorder Drugs Market was valued at USD 1.05 billion in 2025 and is projected to grow to USD 1.13 billion in 2026, with a CAGR of 8.91%, reaching USD 1.91 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.05 billion
Estimated Year [2026] USD 1.13 billion
Forecast Year [2032] USD 1.91 billion
CAGR (%) 8.91%

Concise clinical and commercial orientation to obsessive-compulsive disorder pharmacotherapy that aligns therapeutic nuance with strategic market imperatives

The landscape of pharmacological interventions for obsessive-compulsive disorder demands a clear, concise orientation for stakeholders operating at the intersection of clinical care, product development, and market access. This executive summary opens with a focused introduction to the therapeutic context, highlighting the enduring clinical complexity of OCD, the heterogeneity of patient presentations, and the critical role that pharmacotherapy plays alongside cognitive and behavioral approaches. By emphasizing evidence-based treatment pathways and the diversity of available drug classes, the introduction sets the stage for deeper analysis of market dynamics, regulatory influences, and supply chain considerations.

Transitioning from clinical framing to commercial implications, the introduction underscores the need for integrated strategic thinking that accounts for variations in drug classes, distribution channels, and patient demographics. It clarifies that the subsequent sections synthesize current industry trends, policy shifts, and segmentation intelligence to inform senior-level decisions. This contextual foundation ensures readers appreciate how clinical realities map onto commercial levers, enabling data-driven choices about portfolio prioritization, patient access strategies, and partnership opportunities.

Detailed account of converging scientific, regulatory, and commercial forces reshaping development pathways and market access strategies for OCD pharmacotherapies

The therapeutic ecosystem for obsessive-compulsive disorder is undergoing transformative shifts driven by evolving clinical evidence, regulatory recalibrations, and technological advances in drug development and delivery. Recent progress in precision psychiatry and more refined phenotyping of OCD subtypes has sharpened target identification and reinvigorated interest in both established antidepressant classes and novel mechanisms of action. Concurrently, regulators are clarifying pathways for adaptive trial designs and expedited review for high-unmet-need indications, which is altering development timelines and investment calculus.

On the commercial front, digital therapeutics and telehealth integration are reshaping patient journey touchpoints and altering prescribing behavior, increasing the importance of real-world evidence and post-market pharmacovigilance. Supply chain optimization, strategic manufacturing partnerships, and an intensifying focus on affordability and payer value frameworks represent additional levers redefining market entry and scale. Collectively, these forces are prompting companies to re-evaluate R&D portfolios, pursue differentiated formulations and delivery routes, and adopt more collaborative commercialization models that align clinical benefit with payers' and providers' evolving expectations.

Comprehensive analysis of how the 2025 United States tariff measures are reshaping supply chains, sourcing decisions, and pricing negotiations across the OCD drug value chain

The cumulative impact of the United States tariffs introduced in 2025 is manifesting across multiple nodes of the obsessive-compulsive disorder drug value chain, forcing stakeholders to reassess supply resilience, cost structures, and sourcing strategies. Tariff-induced input cost pressures have particularly affected active pharmaceutical ingredients and certain specialized excipients, prompting manufacturers to evaluate alternative suppliers and production geographies to preserve margins while maintaining product quality. These adjustments have occurred alongside a broader industry trend toward dual sourcing and enhanced inventory buffering to mitigate future trade policy volatility.

Payers, procurement teams, and hospital formularies are responding by intensifying price negotiations and seeking contracting mechanisms that de-risk exposure to tariff-driven cost variability. Regulators and trade bodies have engaged in targeted dialogue to ensure continuity of critical medicines, and some firms have accelerated onshoring and regional manufacturing investments to circumvent duties and shorten lead times. The tariffs have also elevated the importance of transparent cost modeling and scenario planning, encouraging companies to incorporate trade policy risk into supply chain decisions and to explore strategic alliances that can absorb or offset tariff impacts while preserving patient access.

Strategic segmentation synthesis that maps drug classes, channels, formulations, and patient cohorts to differentiated commercial and clinical imperatives

A nuanced segmentation lens reveals the differentiated commercial dynamics that govern OCD pharmacotherapy demand, uptake, and competitive pressures. When examining drug class, major antidepressant categories including monoamine oxidase inhibitors, serotonin-norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, and tricyclic antidepressants each present distinct efficacy and tolerability profiles, with MAOIs further represented by phenelzine and tranylcypromine, SNRIs by desvenlafaxine, duloxetine, and venlafaxine, SSRIs by citalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline, and TCAs by amitriptyline, clomipramine, and imipramine; these therapeutic nuances influence prescribing patterns, switching behavior, and long-term adherence.

Distribution channel dynamics encompass hospital pharmacies, online pharmacies, and retail pharmacies, each serving different patient access needs and reimbursement pathways and shaping how products are merchandised and supported. Drug type segmentation across brand and generic markets drives pricing strategies, lifecycle management approaches, and commercialization investments. Route of administration-oral versus parenteral-affects formulation priorities, adherence support requirements, and clinical settings for administration. End-user distinctions among clinics, hospitals, and households reflect divergence in procurement cycles, care delivery models, and patient education imperatives. Finally, patient age group segmentation into adult and pediatric cohorts requires distinct safety considerations, dosing paradigms, and regulatory dossiers, making a tailored approach essential for clinical adoption and market penetration.

Actionable regional intelligence explaining how Americas, Europe Middle East & Africa, and Asia-Pacific market dynamics demand tailored commercialization and access strategies

Regional nuances materially affect how OCD pharmacotherapies are developed, reimbursed, and delivered, demanding geographically customized strategies. In the Americas, access frameworks, payer heterogeneity, and a robust private market shape commercialization tactics and prioritization of evidence generation that supports formulary inclusion and reimbursement. This region emphasizes outcomes-oriented contracting and real-world evidence to demonstrate value within diverse healthcare delivery models.

Europe, the Middle East & Africa present a mosaic of regulatory approaches and reimbursement environments, with pronounced differences between centralized regulatory pathways, national health technology assessment requirements, and emerging market constraints; companies must balance harmonized clinical data packages with localized health economic models. The Asia-Pacific region displays rapid adoption of digital health modalities and an expanding role of domestically manufactured generics and biosimilars, necessitating strategies that account for local manufacturing partnerships, variable payer coverage, and cultural dimensions of mental health care. Across all regions, evolving patient advocacy, telemedicine uptake, and regional manufacturing considerations inform differentiated market entry and scaling choices.

Insightful corporate behavior and competitive positioning analysis highlighting innovation, lifecycle management, and partnership strategies shaping OCD therapeutic portfolios

Competitive and corporate behavior within the obsessive-compulsive disorder drug space reflects a blend of innovation investment, lifecycle management, and partnerships to address access and differentiation. Organizations are increasing investment in late-stage clinical programs that seek improved efficacy or tolerability versus existing standards, while simultaneously optimizing portfolios through formulation improvements and extended-release or combination approaches. Research collaborations with academic centers and digital health vendors are becoming more common as companies pursue complementary nonpharmacologic solutions to enhance overall outcomes.

At the same time, generic entrants and established off-patent molecules exert pressure on pricing and reimbursement, compelling originators to emphasize brand value via outcomes data and support services. Strategic licensing, co-promotion, and regional manufacturing agreements are being used to accelerate distribution and reduce supply risk. Investor scrutiny around R&D productivity has prompted tighter prioritization of programs with clear clinical differentiation or regulatory incentives. Overall, corporate strategies are converging on a balanced mix of innovation, cost discipline, and partnership to sustain competitiveness while addressing payer and patient expectations.

Practical and high-leverage recommendations for executives to strengthen supply resilience, evidence generation, and value-driven commercialization in OCD therapeutics

Industry leaders seeking to strengthen their position in the OCD therapeutic domain should prioritize a set of pragmatic, high-impact actions that enhance resilience and commercial differentiation. First, align clinical development choices with payer evidence requirements by integrating health economics and outcomes research early in trial design to shorten the path to formulary acceptance. Simultaneously, fortify supply chains through regional diversification and strategic manufacturing agreements to reduce exposure to trade policy shocks and ensure continuity of supply.

Leaders should also invest in digital and patient-support services that improve adherence and real-world outcomes, thereby reinforcing product value propositions. Partnerships with behavioral health providers and telemedicine platforms can extend reach into under-served patient segments and create integrated care solutions. Finally, adopt dynamic pricing and contracting frameworks that reflect value delivered across varied care settings, and maintain an active watch on regulatory and reimbursement shifts to respond nimbly. Executing these coordinated moves will better position companies to deliver clinically meaningful innovations while safeguarding access and commercial viability.

Transparent, multi-method research approach integrating primary stakeholder interviews with systematic secondary evidence to deliver reliable, reproducible strategic insights

The research underpinning this executive analysis combines primary and secondary approaches to ensure robust, triangulated insights. Primary engagement included structured interviews with clinicians, payers, procurement officers, and manufacturing experts to capture operational realities, prescribing behavior, and access constraints across care settings. Secondary research entailed systematic reviews of peer-reviewed clinical literature, regulatory guidance documents, clinical trial registries, and publicly available safety reports to validate therapeutic trends and evidence gaps.

Analytical techniques integrated qualitative synthesis with quantitative trend analysis where appropriate, including time-series examination of regulatory filings, patent landscapes, and supply chain event histories. Cross-validation was achieved through subject matter expert consultations and scenario-based sensitivity checks to test assumptions about supply risk and policy impact. Ethical considerations and data provenance were maintained throughout the process, with a clear emphasis on transparency and reproducibility of methods to support confident decision-making by stakeholders.

Executive synthesis emphasizing the imperative to integrate clinical differentiation, supply resilience, and patient-centric strategies to achieve sustainable impact in OCD therapeutics

In conclusion, the contemporary OCD therapeutic environment is characterized by simultaneous pressures and opportunities across clinical, regulatory, and commercial dimensions. Advances in clinical understanding and the emergence of complementary digital interventions are opening pathways for improved patient outcomes, while trade policy shifts and intensified generic competition are reshaping cost and supply dynamics. Decision-makers must therefore integrate evidence generation, supply chain resilience, and patient-centric support services into cohesive strategies that reflect regional market realities and payer expectations.

By prioritizing differentiated clinical value, strengthening manufacturing and sourcing flexibility, and leveraging partnerships to extend care delivery, stakeholders can navigate policy volatility and competitive pressure while improving access for patients. The combined effect of these actions will determine which organizations can sustainably translate scientific progress into broad clinical impact and enduring commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Obsessive-Compulsive Disorder Drugs Market, by Drug Class

  • 8.1. MAOIs
    • 8.1.1. Phenelzine
    • 8.1.2. Tranylcypromine
  • 8.2. SNRIs
    • 8.2.1. Desvenlafaxine
    • 8.2.2. Duloxetine
    • 8.2.3. Venlafaxine
  • 8.3. SSRIs
    • 8.3.1. Citalopram
    • 8.3.2. Fluoxetine
    • 8.3.3. Fluvoxamine
    • 8.3.4. Paroxetine
    • 8.3.5. Sertraline
  • 8.4. TCAs
    • 8.4.1. Amitriptyline
    • 8.4.2. Clomipramine
    • 8.4.3. Imipramine

9. Obsessive-Compulsive Disorder Drugs Market, by Distribution Channel

  • 9.1. Hospital Pharmacy
  • 9.2. Online Pharmacy
  • 9.3. Retail Pharmacy

10. Obsessive-Compulsive Disorder Drugs Market, by Drug Type

  • 10.1. Brand
  • 10.2. Generic

11. Obsessive-Compulsive Disorder Drugs Market, by Route Of Administration

  • 11.1. Oral
  • 11.2. Parenteral

12. Obsessive-Compulsive Disorder Drugs Market, by End User

  • 12.1. Clinics
  • 12.2. Hospitals
  • 12.3. Households

13. Obsessive-Compulsive Disorder Drugs Market, by Patient Age Group

  • 13.1. Adult
  • 13.2. Pediatric

14. Obsessive-Compulsive Disorder Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Obsessive-Compulsive Disorder Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Obsessive-Compulsive Disorder Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Obsessive-Compulsive Disorder Drugs Market

18. China Obsessive-Compulsive Disorder Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc
  • 19.6. Alembic Pharmaceuticals Ltd
  • 19.7. Amneal Pharmaceuticals Inc
  • 19.8. Apotex Inc
  • 19.9. AstraZeneca PLC
  • 19.10. Aurobindo Pharma Limited
  • 19.11. Biogen Inc
  • 19.12. Dr Reddy's Laboratories Ltd
  • 19.13. Eli Lilly and Company
  • 19.14. GlaxoSmithKline plc
  • 19.15. H Lundbeck A/S
  • 19.16. Johnson & Johnson
  • 19.17. Lupin Pharmaceuticals Inc
  • 19.18. Mallinckrodt plc
  • 19.19. Merck & Co Inc
  • 19.20. Novartis AG
  • 19.21. Omeros Corporation
  • 19.22. Otsuka Pharmaceutical Co Ltd
  • 19.23. Pfizer Inc
  • 19.24. Sanofi
  • 19.25. Sun Pharmaceutical Industries Ltd
  • 19.26. Teva Pharmaceutical Industries Ltd
  • 19.27. Torrent Pharmaceuticals Ltd
  • 19.28. Viatris Inc
  • 19.29. Zydus Pharmaceuticals Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PHENELZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TRANYLCYPROMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DESVENLAFAXINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DULOXETINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY VENLAFAXINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CITALOPRAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUOXETINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY FLUVOXAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PAROXETINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SERTRALINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY AMITRIPTYLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLOMIPRAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY IMIPRAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY BRAND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY HOUSEHOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 202. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 203. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 205. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 206. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. GCC OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 236. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 237. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 238. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 239. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 242. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. G7 OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 246. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 247. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 248. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 249. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 250. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 251. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. NATO OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY MAOIS, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SNRIS, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY SSRIS, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY TCAS, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA OBSESSIVE-COMPULSIVE DISORDER DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)